154 related articles for article (PubMed ID: 9808483)
21. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
22. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss.
Buchs N; Helg C; Collao C; Chapuis B; Slosman D; Bonjour JP; Rizzoli R
Osteoporos Int; 2001; 12(10):880-6. PubMed ID: 11716193
[TBL] [Abstract][Full Text] [Related]
24. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
25. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss.
Giannini S; D'Angelo A; Sartori L; Passeri G; Dalle Carbonare L; Crepaldi G
Obstet Gynecol; 1996 Sep; 88(3):431-6. PubMed ID: 8752254
[TBL] [Abstract][Full Text] [Related]
26. Effects of alendronate and calcitonin on bone mineral density in postmenopausal osteoporotic women. An observational study.
Hejdova M; Palicka V; Kucera Z; Vlcek J
Pharm World Sci; 2005 Jun; 27(3):149-53. PubMed ID: 16096879
[TBL] [Abstract][Full Text] [Related]
27. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Yang LJ; Shen FX; Zheng JC; Zhang HL
Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
[TBL] [Abstract][Full Text] [Related]
28. Comparison of calcium and alfacalcidol supplement in the prevention of osteopenia after kidney transplantation.
Berczi C; Asztalos L; Kincses Z; Balogh A; Löcsey L; Balázs G; Lukács G
Osteoporos Int; 2003 Jun; 14(5):412-7. PubMed ID: 12730763
[TBL] [Abstract][Full Text] [Related]
29. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism].
Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K
Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839
[TBL] [Abstract][Full Text] [Related]
30. A prospective randomized study for prevention of postrenal transplantation bone loss.
El-Agroudy AE; El-Husseini AA; El-Sayed M; Mohsen T; Ghoneim MA
Kidney Int; 2005 May; 67(5):2039-45. PubMed ID: 15840055
[TBL] [Abstract][Full Text] [Related]
31. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
[TBL] [Abstract][Full Text] [Related]
32. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonates in the treatment of thalassemia-induced osteoporosis.
Morabito N; Lasco A; Gaudio A; Crisafulli A; Di Pietro C; Meo A; Frisina N
Osteoporos Int; 2002 Aug; 13(8):644-9. PubMed ID: 12181623
[TBL] [Abstract][Full Text] [Related]
34. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.
Floreani A; Zappala F; Fries W; Naccarato R; Plebani M; D'Angelo A; Chiaramonte M
J Clin Gastroenterol; 1997 Jun; 24(4):239-44. PubMed ID: 9252849
[TBL] [Abstract][Full Text] [Related]
35. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
36. Calcitonin versus clodronate in the prevention of ovariectomy-induced osteopenia in rats.
Rico H; Valencia MJ; Villa LF; Hernández ER; Seco C; Sánchez-Atrio A; Revilla M
Clin Rheumatol; 2000; 19(1):47-50. PubMed ID: 10752499
[TBL] [Abstract][Full Text] [Related]
37. Bone loss after cardiac transplantation: effects of calcium, calcidiol and monofluorophosphate.
Meys E; Terreaux-Duvert F; Beaume-Six T; Dureau G; Meunier PJ
Osteoporos Int; 1993 Dec; 3(6):322-9. PubMed ID: 8292843
[TBL] [Abstract][Full Text] [Related]
38. Effect of cyclical intravenous clodronate therapy on bone mineral density and markers of bone turnover in patients receiving home parenteral nutrition.
Haderslev KV; Tjellesen L; Sorensen HA; Staun M
Am J Clin Nutr; 2002 Aug; 76(2):482-8. PubMed ID: 12145026
[TBL] [Abstract][Full Text] [Related]
39. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
[TBL] [Abstract][Full Text] [Related]
40. Osteoporosis and bone morbidity in cardiac transplant recipients.
Lee AH; Mull RL; Keenan GF; Callegari PE; Dalinka MK; Eisen HJ; Mancini DM; DiSesa VJ; Attie MF
Am J Med; 1994 Jan; 96(1):35-41. PubMed ID: 8304361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
